Impact of trastuzumab deruxtecan (T-DXd) and brain stereotactic radiosurgery on intracranial control and radionecrosis risk in HER2-positive or -low breast cancer brain metastases
The Breast · 2026-06 · 87 · 104751
DOI: 10.1016/j.breast.2026.104751 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Breast, 2026-06. Verfasst von Seok-Joo Chun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, South Korea. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Brain Neoplasms, Breast Neoplasms, Radiation Injuries. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center, Korea Ministry of Health and Welfare.
Abstract (Originalsprache)
BACKGROUND: While trastuzumab deruxtecan (T-DXd) demonstrates intracranial efficacy, the potential for radionecrosis (RN) when combined with stereotactic radiosurgery (SRS) remains a concern, given the established risk with other antibody-drug conjugates like T-DM1. This study evaluated the safety and efficacy of T-DXd and SRS in patients with HER2-positive or -low breast cancer brain metastases (BCBM). METHODS: We conducted a multi-center retrospective analysis of 113 patients (461 SRS treatments) treated with SRS and anti-HER2 agents. Patients were stratified into T-DXd(+) (n = 29 patients, 61 treatments) and T-DXd(-) (n = 84 patients, 400 treatments) groups. Endpoints included RN, radionecrosis-free survival (RNFS), and intracranial control outcomes (any intracranial progression, local failure, and distant intracranial metastasis). RESULTS: No cases of RN were observed in the T-DXd(+) group, compared with 11 cases in the T-DXd(-) group (p = 0.028). On multivariate analysis, T-DXd(+) status remained significantly associated with improved RNFS (HR 0.31, p = 0.009). In the treatment-level analysis, the 1-year cumulative incidence of RN was 0% for T-DXd(+) versus 4.3% for T-DXd(-) (p = 0.009). Additionally, T-DXd(+) was associated with significantly better 1-year outcomes for any intracranial progression (40% vs. 76%, p < 0.001), local failure (6.6% vs. 29%, p = 0.002), and distant intracranial metastasis (40% vs. 66%, p = 0.009). All efficacy endpoints remained significant on multivariate analysis. CONCLUSION: Combining T-DXd with SRS demonstrated a favorable safety profile without increasing the risk of radionecrosis. Furthermore, this combination was associated with superior intracranial control, encompassing both local and distant outcomes, supporting the potential of T-DXd combined with SRS as an effective and well-tolerated approach for HER2-positive or -low BCBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, South Korea.
- Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea. Electronic address: kyubokim.ro@gmail.com.
- Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
- Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
- Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Förderung
- National Cancer Center
- Korea Ministry of Health and Welfare
Zitieren
APA
Chun, S. J., Kim, K., Chang, W. I., Kim, Y. B., Paek, S. H., Lee, K. H., Song, J. H., Hong, J. H., Lee, J., Jang, W. I., Kim, T. H., & Shin, K. H. (2026). Impact of trastuzumab deruxtecan (T-DXd) and brain stereotactic radiosurgery on intracranial control and radionecrosis risk in HER2-positive or -low breast cancer brain metastases. The Breast, 87, 104751. https://doi.org/10.1016/j.breast.2026.104751
Vancouver
Chun SJ, Kim K, Chang WI, Kim YB, Paek SH, Lee KH, et al. Impact of trastuzumab deruxtecan (T-DXd) and brain stereotactic radiosurgery on intracranial control and radionecrosis risk in HER2-positive or -low breast cancer brain metastases. The Breast. 2026;87:104751. doi:10.1016/j.breast.2026.104751
BibTeX
@article{Chun2026,
author = {Chun, Seok-Joo and Kim, Kyubo and Chang, Won Ick and Kim, Yong Bae and Paek, Sun Ha and Lee, Kyung-Hun and Song, Jin-Ho and Hong, Ji Hyun and Lee, Jieun and Jang, Won Il and Kim, Tae Hyun and Shin, Kyung Hwan},
title = {Impact of trastuzumab deruxtecan (T-DXd) and brain stereotactic radiosurgery on intracranial control and radionecrosis risk in HER2-positive or -low breast cancer brain metastases},
journal = {The Breast},
year = {2026},
volume = {87},
pages = {104751},
doi = {10.1016/j.breast.2026.104751}
}
EUVIMED